In line, previous studies have already identified RhoA/ROCK as a potential therapeutic target in PAH, as using ROCK inhibitors such as Y-27632 and Fasudil alleviated experimental PH (64, 65). The gene discussed is RHOA; the disease is pulmonary arterial hypertension.